Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront

ASSEMBLY BIOSCIENCES, INC.

2023-Q3 EPS reported -$0.97

Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.
R&D expenses fell to $10.8M from $18.1M YoY due to trial completions and pipeline discontinuations.
Cash $46.2M at Sep 30; $100M upfront from Gilead in Oct extends cash runway into 2H 2025.
Partnership with Gilead includes opt-in rights on current/future pipeline; Gilead contributed two herpesvirus programs.
Appointed Anuj Gaggar, MD, PhD as CMO; expects four development candidates in clinic by end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share.

Period: the third quarter ended September 30, 2023
Net income: Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share
Result: reported results

Exact text from the filing

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-061105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.